Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Deucrictibant · PHA-022121, PHA-121

Small molecule · developed by Pharvaris Netherlands B.V.

Phase 3 Most advanced trial
PHVS Developer
3 Registered trials

What is Deucrictibant?

Deucrictibant is an oral agent given as softgel capsules, an extended-release tablet, or a soft capsule, studied in acquired angioedema due to C1-inhibitor deficiency and in hereditary angioedema.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PHA-022121, PHA-121, PHVS-719
Drug type
Small molecule
Therapy area
Immunology
Developer
Pharvaris Netherlands B.V. (PHVS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
69GCA2KX22

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07266805 Phase 3 Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) Recruiting PHVS
NCT05047185 Phase 2 Hereditary Angioedema Terminated PHVS
NCT07759141 N/A Hereditary Angioedema Available PHVS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

C1 Esterase Inhibitor DeficiencyC1 Inhibitor DeficiencyHereditary AngioedemaHereditary Angioedema - Type 1Hereditary Angioedema - Type 2Hereditary Angioedema AttackHereditary Angioedema Type IHereditary Angioedema Type IIHereditary Angioedema Types I and IIHereditary Angioedema With C1 Esterase Inhibitor Deficiency

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the PHVS page.

Follow PHVS, the company behind Deucrictibant

See PHVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PHVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.